Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to a U.S. Food ... Read more
The multiple sclerosis therapy Tysabri could trigger melanoma, the Southern Network on Adverse Reactions (SONAR) has warned.
Although its investigation failed to demonstrate that melanoma is more common among Tysabri-treated ... Read more
Tecfidera (dimethyl fumarate or DMF) use by multiple sclerosis (MS) patients can result in liver injury and, in rare cases, even severe injury, a study found, leading its researchers to recommend ... Read more
Pin It on Pinterest